Literature DB >> 18616651

Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.

Vincent Wai-Sun Wong1, Grace Lai-Hung Wong, Angel Mei-Ling Chim, Ada Mei-Ling Tse, Steven Woon-Choy Tsang, Alex Yui Hui, Paul Cheung-Lung Choi, Anthony Wing-Hung Chan, Wing-Yee So, Francis Ka-Leung Chan, Joseph Jao-Yao Sung, Henry Lik-Yuen Chan.   

Abstract

OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide. This study aimed to validate the NAFLD fibrosis score in the Chinese population.
METHODS: NAFLD patients were prospectively recruited for liver biopsy and blood tests. The NAFLD fibrosis score was calculated as -1.675 + 0.037 x age (yr) + 0.094 x BMI (kg/m(2)) + 1.13 x impaired fasting glucose/diabetes (yes = 1, no = 0) + 0.99 x AST/ALT ratio-0.013 x platelet (x10(9)/L)-0.66 x albumin (g/dL). Advanced fibrosis was defined as stage 3 to 4 fibrosis.
RESULTS: One hundred sixty-two patients (age 46 +/- 10 yr, male 59%) were included in the study. Advanced fibrosis was found in 18 (11%) patients. Only 11 of 128 patients with the NAFLD fibrosis score below the proposed low cutoff point (<-1.455) were under-staged, resulting in a high negative predictive value of 91%. Only two patients exceeded the proposed high cutoff point (>0.676), but neither had advanced fibrosis. If the NAFLD fibrosis score was implemented in the Chinese population, 79% of liver biopsies could be avoided.
CONCLUSIONS: The NAFLD fibrosis score has high negative predictive value in excluding advanced fibrosis in the Chinese population, and can reduce the burden of liver biopsy in the vast majority of cases. Since there were few cases of advanced fibrosis in this cohort, this study had limited power in validating the high cutoff point.

Entities:  

Mesh:

Year:  2008        PMID: 18616651     DOI: 10.1111/j.1572-0241.2008.01933.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  33 in total

Review 1.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Current status of therapy in nonalcoholic Fatty liver disease.

Authors:  Scott McNear; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

3.  A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Sanjiv Mahadeva
Journal:  Hepatol Int       Date:  2014-12-06       Impact factor: 6.047

4.  Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease.

Authors:  Grace Lai-Hung Wong; Henry Lik-Yuen Chan
Journal:  Hepatol Int       Date:  2015-03-11       Impact factor: 6.047

Review 5.  Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

Authors:  Bassem Matta; Tzu-Hao Lee; Keyur Patel
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

Review 6.  The future liver of the Asia pacific: fatter and firmer from more fructose and fortune?

Authors:  Suzanne E Mahady; Jacob George
Journal:  J Clin Exp Hepatol       Date:  2012-12-28

Review 7.  Can NASH be diagnosed, graded, and staged noninvasively?

Authors:  Garfield A Grandison; Paul Angulo
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

8.  Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016.

Authors:  Donghee Kim; Won Kim; Adeyinka C Adejumo; George Cholankeril; Sean P Tighe; Robert J Wong; Stevan A Gonzalez; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Hepatol Int       Date:  2019-01-29       Impact factor: 6.047

9.  The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.

Authors:  Tracey G Simon; Kathleen E Corey; Christopher P Cannon; Michael Blazing; Jeong-Gun Park; Michelle L O'Donoghue; Raymond T Chung; Robert P Giugliano
Journal:  Int J Cardiol       Date:  2018-05-26       Impact factor: 4.164

Review 10.  Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshio Sumida; Atsushi Nakajima; Yoshito Itoh
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.